Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation

Waleed, Khalid Bin; Xia, Yin; Yang, Xiaolei; Dai, Bai-Ling; Liu, Yang; Wang, Zhao; Guan, Xiaoqian; Gao, Lianjun; Yves, De Greef; Wang, Lili; Tse, Gary; Cappato, Riccardo; Wu, Shulin; Xia, Yunlong

doi:10.1016/j.ijcard.2019.02.054

Cited by 20 publications

(19 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…14 In that analysis, RF PP ablation was found to be the most cost-effective option, with an ICER of £9764 per QALY technology is considered to be a significant improvement upon older technology. [40][41][42][43][44] A recent network meta-analysis (Gupta 2020) found increased freedom from AF in the latest generations of RF technology compared to noncontact force sensing. Our model included the costs of state-of-the-art radiofrequency ablation, but not the clinical outcomes, thus in reality, the cost-effectiveness of ablation may be further improved.…”

Section: Comparison With Existing Literaturementioning

confidence: 99%

Cost‐effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom

Leung

Imhoff

Marshall

et al. 2021

Cardiovasc electrophysiol

View full text Add to dashboard Cite

is an employee of, and Diana Frame and Peter J. Mallow are consultants of, CTI Clinical Trial and Consulting Services, which is a consultant to Biosense Webster, the study sponsor. Mark M. Gallagher has received research funding from Attune Medical and has acted as a consultant and paid speaker for Boston Scientific and Cook Medical. Lisa W. M. Leung has received research support from Attune Medical.

show abstract

Section: Comparison With Existing Literaturementioning

confidence: 99%

Cost‐effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom

Leung

Imhoff

Marshall

et al. 2021

Cardiovasc electrophysiol

View full text Add to dashboard Cite

show abstract

“…In patients with AF, increased pre-ablation levels of BNP, ANP, IL-6 and hsCRP are associated with a greater risk of AF recurrence after ablation 28. However, studies focusing on the effect of CA on proinflammatory cytokines have shown mixed results, and in most of them, the concentrations remained unchanged in patients with AF after successful AF ablation with SR maintenance after 12 months 29 30…”

Section: Introductionmentioning

confidence: 99%

“… 28 However, studies focusing on the effect of CA on proinflammatory cytokines have shown mixed results, and in most of them, the concentrations remained unchanged in patients with AF after successful AF ablation with SR maintenance after 12 months. 29 30 …”

Section: Introductionmentioning

confidence: 99%

Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial)

et al. 2022

View full text Add to dashboard Cite

IntroductionAtrial fibrillation (AF), with a prevalence of 2%, is the most common cardiac arrhythmia. Catheter ablation (CA) has been documented to be superior to treatment by antiarrhythmic drugs (AADs) in terms of sinus rhythm maintenance. However, in obese patients, substantial weight loss was also associated with AF reduction. So far, no study has compared the modern non-invasive (AADs combined with risk factor modification (RFM)) approach with modern invasive (CA) treatment. The aim of the trial is to compare the efficacy of modern invasive (CA) and non-invasive (AADs with risk factor management) treatment of AF.Methods and analysisThe trial will be a prospective, multicentre, randomised non-inferiority trial. Patients with symptomatic AF and a body mass index >30 will be enrolled and randomised to the CA or RFM arm (RFM+AAD) in a 1:1 ratio. In the CA arm, pulmonary vein isolation (in combination with additional lesion sets in non-paroxysmal patients) will be performed. For patients in the RFM+AAD arm, the aim will be a 10% weight loss over 6–12 months, increased physical fitness and a reduction in alcohol consumption. The primary endpoint will be an episode of AF or regular atrial tachycardia lasting >30 s. The secondary endpoints include AF burden, clinical endpoints associated with AF reoccurrence, changes in the quality of life assessed using dedicated questionnaires, changes in cardiorespiratory fitness and metabolic endpoints. An AF freedom of 65% in the RFM+AAD and of 60% in the CA is expected; therefore, 202 patients will be enrolled to achieve the non-inferiority with 80% power, 5% one-sided alpha and a non-inferiority margin of 12%.Ethics and disseminationThe PRAGUE-25 trial will determine if modern non-invasive AF treatment strategies are non-inferior to CA. The study was approved by the Ethics Committee of the University Hospital Kralovske Vinohrady. Results of the study will be disseminated on scientific conferences and in peer-reviewed scientific journals. After the end of follow-up, data will be available upon request to principal investigator.Trial registration numberClinicalTrials.gov Registry (NCT04011800).

show abstract

“…The data was collected from 58 symptomatic paroxysmal atrial fibrillation (AF) defined according to expert consensus statement [2] those who undergone first-time CB (n = 29) and RF (n-29) ablation (September 2016–December 2017) at the First Affiliated Hospital of Dalian Medical University as previously described [1], [2], [3], [4].…”

Section: Experimental Design Materials and Methodsmentioning

confidence: 99%

Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation

et al. 2019

Self Cite

View full text Add to dashboard Cite

Data presented in this article are supplementary analyzed tables and individual raw data to our research article entitled “Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation (Bin Waleed K et al., 2019) [1]”. These supplementary analyzed tables and individual raw data included platelet activation biomarkers [P-selectin (CD62P), CD40 ligand (CD40L), platelet factor-4 (PF-4), mean platelet volume (MPV), platelet-leukocyte ratio (P-LCR), and platelet distribution width (PDW)]; and inflammatory biomarkers [high sensitivity CRP (hs-CRP) and interleukin-6 (IL-6)] after cryoballoon (CB) and radiofrequency (RF) ablation. The provided raw data are intended to show the difference at short and long-term in platelet and inflammatory biomarkers values between CB and RF ablation.

show abstract

Short and long-term changes in platelet and inflammatory biomarkers after cryoballoon and radiofrequency ablation

Cited by 20 publications

References 27 publications

Cost‐effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom

Cost‐effectiveness of catheter ablation versus medical therapy for the treatment of atrial fibrillation in the United Kingdom

Catheter ablation versus antiarrhythmic drugs with risk factor modification for treatment of atrial fibrillation: a protocol of a randomised controlled trial (PRAGUE-25 trial)

Data for short and long-term prothrombotic biomarkers after cryoballoon and radiofrequency ablation

Contact Info

Product

Resources

About